Subarachnoid hemorrhage in a post-PCI patient on antiplates is a double jeopardy. Antiplatelet drug(s) is essential in a patient undergoing PTCA with stenting. On the other hand, intracranial hemorrhage is a contraindication to use of such drugs. Commonly antiplatelet drugs are stopped, and restarted 6 weeks or more after stabilization. Clipping of the culprit vessel may have an important role.
Knowing the cause of the haemorrhage and having it treated eg clipping, coiling, is the ideal way before deciding on DAPT. Another important issue is on the need/indications for PCI. In a high risk, untreated patient with SAH, perhaps the only accepted indication is unstable ACS with original Class I indication for PCI.
If I understand well, you are talking about a patient who already had PCI+ stenting, and then SAH. This is one of the greatest unanswered clinical problems, which doesn't have just one solution. In my opinion, as Dr Oteh M said, it depends on how serious the SAH was, on how has it been resolved (if possible), and on how much time ago the patient had PCI and stenting. The second anti-platelet drug (tyeno) must be stopped. About Aspirin I have no data in patient at intermediate or high thrombotic risk, whereas I usually decide about withdrawal in low thrombotic risk (e.g. 12 months after DES or 6 months after BMS).
Regards